Allergan plc (NYSE:AGN) – Research analysts at Gabelli decreased their FY2019 EPS estimates for Allergan in a research note issued on Wednesday, October 31st. Gabelli analyst K. Kedra now anticipates that the company will post earnings per share of $16.20 for the year, down from their previous estimate of $17.05. Gabelli also issued estimates for Allergan’s FY2020 earnings at $18.10 EPS, FY2021 earnings at $20.05 EPS and FY2022 earnings at $21.50 EPS.
AGN has been the subject of several other research reports. Guggenheim initiated coverage on Allergan in a report on Monday, October 8th. They issued a “buy” rating for the company. ValuEngine raised Allergan from a “strong sell” rating to a “sell” rating in a report on Friday, September 21st. Raymond James cut their price target on Allergan from $232.00 to $198.00 and set a “buy” rating for the company in a report on Wednesday, October 31st. Credit Suisse Group set a $213.00 price objective on Allergan and gave the stock a “buy” rating in a research report on Friday, July 13th. Finally, Zacks Investment Research upgraded Allergan from a “hold” rating to a “buy” rating and set a $193.00 price objective for the company in a research report on Tuesday, July 24th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the stock. Allergan presently has a consensus rating of “Buy” and a consensus price target of $210.18.
NYSE:AGN opened at $165.47 on Monday. Allergan has a one year low of $142.81 and a one year high of $197.00. The company has a quick ratio of 0.78, a current ratio of 0.92 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $54.99 billion, a P/E ratio of 10.12, a P/E/G ratio of 1.29 and a beta of 1.31.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.89 billion. During the same quarter last year, the firm earned $4.15 earnings per share. The business’s revenue for the quarter was down 3.0% on a year-over-year basis.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be given a $0.72 dividend. The ex-dividend date is Friday, November 9th. This represents a $2.88 annualized dividend and a yield of 1.74%. Allergan’s payout ratio is 17.61%.
In other news, Director Joseph H. Boccuzi purchased 900 shares of the stock in a transaction dated Thursday, August 30th. The stock was acquired at an average cost of $190.59 per share, for a total transaction of $171,531.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction dated Thursday, September 6th. The shares were purchased at an average price of $190.64 per share, with a total value of $1,906,400.00. The disclosure for this purchase can be found here. Corporate insiders own 0.37% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in AGN. Kempner Capital Management Inc. purchased a new position in shares of Allergan during the second quarter worth $1,432,000. DAVENPORT & Co LLC boosted its position in shares of Allergan by 75.1% during the second quarter. DAVENPORT & Co LLC now owns 2,282 shares of the company’s stock worth $380,000 after buying an additional 979 shares during the period. Fulton Bank N.A. boosted its position in shares of Allergan by 5.8% during the second quarter. Fulton Bank N.A. now owns 8,734 shares of the company’s stock worth $1,457,000 after buying an additional 479 shares during the period. Osborn Williams & Donohoe LLC boosted its position in shares of Allergan by 58.2% during the second quarter. Osborn Williams & Donohoe LLC now owns 1,902 shares of the company’s stock worth $317,000 after buying an additional 700 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Allergan by 4.8% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 19,810 shares of the company’s stock worth $3,302,000 after buying an additional 900 shares during the period. Institutional investors and hedge funds own 77.55% of the company’s stock.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.